Trial Design

A look at some of the leading causes of study failure and explain how improving medication adherence could be the key to risk mitigation.

The success of the decentralized model hinges on coordination between stakeholders across the supply chain to ensure that date is secure, medication is delivered on time, and in proper condition.

COVID-19 forces life sciences industry to make long overdue changes.

Pandemic-forced move to remote monitoring calls for industry-wide collaboration.

Upcoming Clinical Trials Day allows industry to look back—and forward.

How asking better questions and leveraging site databases can expand access to more patients.

Analysis of 330,000 clinical trials calls for improved protocol design process.

Operational and patient burden considerations for self-collection of blood specimens in clinical trials

A look forward to 2021 for the clinical trials industry.

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Regulatory concerns remain despite industry's quick adaptation of decentralized trials.

The industry wide shift to decentralized clinical trials includes considerations for sponsors and CROs such as global availability, global technology, and data integration.

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.

Both quality personnel and the FDA have predicted some of the issues with pandemic operations, but much is still unknown on the impact these rapidly implemented pandemic processes.

Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.

Findings from a Tufts study examining the effects of COVID-19 on clinical trials.

Tips for reducing site queries and improving workflows.

With the assistance of mobile research nursing, in-home visits provide solid alternative to trial participants, especially during COVID-19.

Decentralized clinical trials (DCTs) have ignited clinical transformation while the COVID-19 pandemic has fueled their rapid expansion.

ACT's Editor-in-Chief, Lisa Henderson, assesses the sustainability of remote trials.

Jody Casey of Elligo Health Research gives insight into the issue of diversity in trials and what needs to be done to correct it.

Disa Lee Choun, Head of Innovation at UCB, discusses how they have fostered a culture of innovation, and how the investment in piloting has benefitted clinical operational implementation during the COVID-19 pandemic.

The use of virtual trials will surge in the future and could become the de facto standard for clinical studies, says a recent Pistoia Alliance poll.

Tips for reducing site queries and improving workflows.

A look at how real world data and real world evidence are shaping more decentralized trial designs for potential COVID-19 treatments.